On April 11, 2022, the Board of Directors of Sera Prognostics, Inc. appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022, as a director to the Board to serve as a Class I Director with a term expiring at the Company's 2022 annual meeting of stockholders. Dr. Barlow has served as Chief Executive Officer of Jane Barlow & Associates, LLC, a consulting firm focused on value-based health care services, since January 2017, and Executive Vice President and Chief Clinical Officer at Real Endpoints, a data, analytics, and advisory firm, since January 2017. She currently serves on the board of directors of ContraFect Corp., a publicly traded biotechnology company, and Viracta Therapeutics, Inc., a publicly traded precision oncology company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.85 USD | +2.07% | +0.93% | +81.44% |
03-28 | Sera Prognostics Insider Sold Shares Worth $727,853, According to a Recent SEC Filing | MT |
03-27 | Sera Prognostics Insider Sold Shares Worth $364,484, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.44% | 354M | |
0.00% | 7.08B | |
-11.41% | 2.91B | |
-6.89% | 2.85B | |
-27.64% | 1.83B | |
-2.47% | 1.16B | |
-6.63% | 1.07B | |
-10.95% | 831M | |
+0.83% | 767M | |
-9.85% | 747M |
- Stock Market
- Equities
- SERA Stock
- News Sera Prognostics, Inc.
- Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director